Julie Lamb

About the Author Julie Lamb

Julie graduated with a Bachelor of Arts in English with a focus on creative writing from the University of Louisville.

Tech Guru Gene Munster Says Tesla (TSLA) Profitability in Reach by Q3; Here’s Why

Loup Ventures’ Gene Munster is bullish on Tesla’s massive reorganization, which encouragingly will not throw Model 3 production off course.

History Says Advanced Micro Devices (AMD) Set to Win Key Market Share in x86 CPUs

Rosenblatt’s Hans Mosesmann offers his bullish two cents on AMD as he forecasts rival INTC trailing dangerously behind in the CPU playing field.

Helios and Matheson (HMNY): Is the Risk/Reward Here Compelling After All?

Is there a bullish case to be made for Helios and Matheson (NASDAQ:HMNY) stock? Worthy of note, this once shining tech play has …

Nomura Dishes Key Insights on Intel (INTC) Following Meeting with CEO Brian Krzanich

Nomura’s Romit Shah dives into Intel’s market prospects, from server share threats to yielding 10nm following a meeting with management.

Micron (MU): What Will the Next Batch of iPhones Mean for DRAM Demand? Top Analyst Weighs In

RBC Capital’s Amit Daryanani sees mobile DRAM demand continuing to be robust and MU shares tracking toward $8.00+ in EPS.

Here’s Why Applied Optoelectronics Inc (AAOI) Shares Are Taking a 7% Nosedive

Rosenblatt’s Jun Zhang has approached AAOI stock from the bearish camp, negative on rising “price war headwinds.”

Tesla (TSLA) Model 3 Production Story Compels This Analyst to Boost Price Target

GBH Insights’ Daniel Ivews now spotlights 18% in return potential for TSLA stock.

Qualcomm (QCOM): Is an Approved NXPI Deal on the Horizon? Top Analyst Says Yes

RBC Capital’s Amit Daryanani sees increasingly favorable odds for QCOM to at last close its highly anticipated NXPI deal.

Quant Wizard Cliff Asness Takes Some Profits off the Table from Micron (MU), Charges Up Advanced Micro Devices (AMD)

Invest like Cliff Asness, master of the quant trade game, who took a slice off his MU holding while hiking up AMD in Q1.

Verastem (VSTM): Is There More Fuel For The Bulls?

FBR’s George Zavoico believes strong data for Verastem’s lead drug candidate duvelisib helped impress Japan’s Yakult Honsha.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts